The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2131-2141

  Toner, A P ^a   McLaughlin, F ^b   Giles, F J ^a   Sullivan, F J ^a,c   O'Connell, E ^a   Carleton, L A ^a   Breen, L ^d   Dunne, G ^d   Gorman, A M ^a   Lewis, J D ^b   Glynn, S A ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b Elara Pharmaceuticals GmbH   (Germany)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

^d DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

chemotherapeutic; Hif1; MDR1 drug resistance; prostate cancer; taxane; toluidine sulphonamide

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; EL 102; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SULFONAMIDE; TOLUIDINE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MALE; MICE; MICROTUBULES; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SULFONAMIDES; TAXOIDS; TOLUIDINES; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885946267     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.537     Document Type: Article

References (33)

1. Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G (2010) Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer. Future Oncol 6(5): 665-679.
2. Antonarakis ES, Eisenberger MA (2013) Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: Time to learn from past experiences. J Clin Oncol 31(14): 1709-1712.
3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26(2): 242-245.
4. Clynes M, Redmond A, Moran E, Gilvarry U (1992) Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A. Cytotechnology 10(1): 75-89.
5. Collins DM, Crown J, O?Donovan N, Devery A, O?Sullivan F, O?Driscoll L, Clynes M, O?Connor R (2010) Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs 28(4): 433-444.
6. Douros J, Suffness M (1981) New natural products under development at the National Cancer Institute. Recent Results Cancer Res 76: 153-175.
7. Dunne G, Breen L, Collins DM, Roche S, Clynes M, O?Connor R (2011) Modulation of P-gp expression by lapatinib. Invest New Drugs 29(6): 1284-1293.
8. Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, Nouyrigat P, Foa C, Kaphan R (2006) Phase II trial evaluating a docetaxelcapecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 107(4): 738-745.
9. Garcia JA, Hutson TE, Shepard D, Elson P, Dreicer R (2011) Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: Results from a phase 2 trial. Cancer 117(4): 752-757.
10. German Animal Protection Law and the UICCR (2010) ?Guidelines for the welfare and use of animals in cancer research?. Brit J Cancer 102: 1555-1577.
11. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1): 38-47.
12. Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H (2013) Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol 138C: 248-256.
13. Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7(2): 107-117.
14. Keenan J, Murphy L, Henry M, Meleady P, Clynes M (2009) Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 9(6): 1556-1566.
15. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, Wake K, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M (2007) Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 51(5): 1252-1258.
16. Manfredi JJ, Horwitz SB (1984) Taxol: An antimitotic agent with a new mechanism of action. Pharmacol Therap 25(1): 83-125.
17. Martin A, Clynes M (1991) Acid phosphatase: endpoint for in vitro toxicity tests. In Vitro Cell Dev Biol 27A(3 Pt 1): 183-184.
18. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15(2): 723-730.
19. Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T (2012) Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol 10: 1.
20. O?Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12): 2317-2325.
21. O?Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O?Connor D, O?Connor R, Devery A, Corcoran C, Rani S, O?Driscoll L, Fitzpatrick JM, Watson RW (2011) Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 10: 126.
22. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ (2003) A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormonerefractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98(12): 2592-2598.
23. Peinemann F, Grouven U, Hemkens LG, Bartel C, Borchers H, Pinkawa M, Heidenreich A, Sauerland S (2011) Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev (7): CD008871.
24. Petrylak DP, Tangen CM, Hussain MH, Lara Jr. PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520.
25. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK (2012) Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Cancer 118(19): 4777-4784.
26. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82(15): 1247-1259.
27. Seruga B, Ocana A, Tannock IF (2011) Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8(1): 12-23.
28. Tester W, Ackler J, Tijani L, Leighton J (2006) Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormonerefractory prostate carcinoma. Cancer J 12(4): 299-304.
29. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3): 1112-1116.
30. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9): 2325-2327.
31. Wendt B, Mulbaier M, Wawro S, Schultes C, Alonso J, Janssen B, Lewis J (2011) Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: Alleviating drug-drug interactions through use of PubChem data and comparative molecular field analysis guided synthesis. J Med Chem 54(11): 3982-3986.
32. Womble PR, VanVeldhuizen PJ, Nisbet AA, Reed GA, Thrasher JB, Holzbeierlein JM (2011) A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol 186(3): 882-887.
33. Zhang B, Suer S, Livak F, Adediran S, Vemula A, Khan MA, Ning Y, Hussain A (2012) Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Mol Pharmacol 82(2): 310-321.